Eli Lilly and Co at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Great. Well, good afternoon, everybody, and thanks for joining us for the next session. I'm Matthew Harrison, one of the biopharma analysts here at Morgan Stanley. Very pleased to have Eli Lilly with us for the next session.
Before we get started, I need to read a disclosure statement. Please note that all important disclosures, including personal holdings disclosures and Morgan Stanley disclosures, appear on the Morgan Stanley public website at morganstanley.com/researchdisclosures.
So pleased to have Mike Mason with us from Lilly, who runs Diabetes. And we've got a wide range of topics to talk about. So looking forward to it.
Questions & Answers
Mike, I thought we could start with tirzepatide. Obviously, people are focused on the filing there and sort of next steps. So maybe you could just remind us where you are in terms of the filing and how that's progressing?
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
